Perinatal Arterial Stroke Treated With Stromal Cells Intranasally

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

July 27, 2021

Study Completion Date

July 27, 2021

Conditions
Perinatal Arterial Ischemic StrokeNeonatal Stroke
Interventions
BIOLOGICAL

Mesenchymal Stem Cells

One dose of 50x10\^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.

Trial Locations (1)

3584 EA

Wilhelmina Childrens Hostpital/University Medical Center Utrecht, Utrecht

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

The University of Texas Health Science Center at San Antonio

OTHER

lead

UMC Utrecht

OTHER

NCT03356821 - Perinatal Arterial Stroke Treated With Stromal Cells Intranasally | Biotech Hunter | Biotech Hunter